Table 1 |
|||
|
Tau sites phosphorylated by GSK-3β. |
|||
|
sites |
Reynoldsa |
Connellb |
Rankinc |
|
|
|||
|
T175 |
+ |
* |
|
|
T181 |
+ |
* |
|
|
S199 |
+ |
+ |
+ |
|
T205 |
+ |
||
|
T212 |
+ |
+ |
+ |
|
S214 |
+ |
||
|
T217 |
+ |
+ |
+ |
|
T231 |
+ |
+ |
+ |
|
S235 |
+ |
+ |
* |
|
S262 |
+ |
||
|
S356 |
+ |
||
|
S396 |
+ |
+ |
+ |
|
S400 |
+ |
+ |
+ |
|
S404 |
+ |
+ |
+ |
|
S409 |
+ |
||
|
S422 |
|||
|
|
|||
|
Identification of in vitro phosphorylated sites by mass spectrometry a Reynolds, et al. study [37] b Connell, et al. study [38] c Identification of in vitro phosphorylated sites by phosphorylation site-specific antibodies. Antibodies were unavailable for those sites marked with an asterisk. S422, not identified by either mass spectrometry or antibody analysis, was a negative control. |
|||
|
Rankin et al. Molecular Neurodegeneration 2007 2:12 doi:10.1186/1750-1326-2-12 |
|||